BC Week In Review | Feb 27, 2012
Company News

Critical Pharmaceuticals, University of Nottingham deal

The university and Critical Pharmaceuticals partnered to develop an intranasal formulation of teriparatide to treat osteoporosis. The university's Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) will provide a grant for...
BC Week In Review | Dec 5, 2011
Company News

Asahi Kasei sales and marketing update

Asahi launched Teribone teriparatide in Japan to treat osteoporosis in patients with a high risk of fracture. The National Health Insurance (NHI) price of the subcutaneous formulation of parathyroid hormone ( hPTH 1-34 ) is ¥12,971 ($167.33)...
BC Week In Review | Oct 17, 2011
Company News

Zosano, Asahi Kasei Pharma deal

Zosano granted Asahi exclusive rights in China, Japan, Korea and Taiwan to use Zosano's ZP Patch microprojection delivery technology to develop and commercialize a transdermal formulation of Asahi's once-weekly subcutaneous osteoporosis drug Teribone teriparatide. Zosano...
BC Extra | Oct 11, 2011
Company News

Asahi, Zosano in deal for transdermal osteoporosis drug

Zosano Pharma Inc. (Fremont, Calif.) granted Asahi Kasei Pharma Corp. (Tokyo, Japan) exclusive rights in China, Japan, Korea and Taiwan to use Zosano's ZP Patch microprojection delivery technology to develop and commercialize a transdermal formulation...
Items per page:
1 - 4 of 4